Equilibre BioPharmaceuticals Corp. — Form D

Equilibre BioPharmaceuticals Corp. of NEW YORK, NY, a company, filed a Form D exempt-offering notice with the SEC on 2020-11-12. The offering totals $35.8M, of which $25.8M was reported sold. Industry: Pharmaceuticals.

Offering

Issuer

Officers, directors & promoters (20)

NameRoleLocation
Sam WaksalExecutive OfficerNew York, NY
Peter SimonDirectorDenver, CO
Joel MarcusDirectorSouth San Francisco, CA
David FriedmanDirectorNEW HAVEN, CT
Philip BarachDirectorPortland, ME
Christopher M ThornDirectorNew York, NY
Christopher M ThornExecutive OfficerNew York, NY
Christina A RamirezDirectorNew York, NY
Peter M SimonDirectorNew York, NY
Francois A MaisonrougeDirectorNew York, NY
Francois MaisonrougeDirectorNew York, NY
Steven GordonDirectorNew York, NY
Steven GordonExecutive OfficerNew York, NY
Samuel WaksalDirectorNew York, NY
Samuel WaksalExecutive OfficerNew York, NY
DAVID A FRIEDMANDirectorEVANSTON, IL
Steven N GordonDirectorNew York, NY
Steven N GordonExecutive OfficerNew York, NY
PHILIP A BARACHDirectorLOS ANGELES, CA
PHILIP A BARACHExecutive OfficerLOS ANGELES, CA

Other filings by this issuer (3)

FiledFormOfferingSold
2022-12-01D$6.0M$6.0M
2022-12-01D/A$6.0M$6.0M
2022-01-20D$25.0M$15.9M

More